- Home
- Products
- Customized ADCs
- ITGAV+ITGB3
- Anti-ITGAV+ITGB3 (Etaracizumab)-MC-MMAF ADC
Anti-ITGAV+ITGB3 (Etaracizumab)-MC-MMAF ADC (CAT#: ADC-W-2128)
This ADC product is comprised of an anti-ITGAV+ITGB3 monoclonal antibody conjugated via a MC linker to MMAF. The MMAF is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the cell, MMAF binds to tubulins, interrupts microtubule dynamics, and subsequently, induces cell death.
- ADC Target
- ADC Antibody
- ADC Linker
- ADC payload drug
- Name
- ITGAV+ITGB3
- Alternative Names
- ITGAV+ITGB3
- Overview
- Integrins are integral cell-surface proteins composed of an alpha chain and a beta chain. They are known to participate in cell adhesion as well as cell-surface mediated signalling. Integrins are heterodimeric integral membrane proteins composed of an alpha chain and a beta chain. CD51 encodes integrin alpha chain V. The I-domain containing integrin alpha V undergoes post-translational cleavage to yield disulfide-linked heavy and light chains, that combine with multiple integrin beta chains to form different integrins. Alpha-V integrins have been implicated in many developmental processes and are therapeutic targets for inhibition of angiogenesis and osteoporosis.
- Overview
- Humanized Anti-ITGAV+ITGB3 IgG1 antibody, Etaracizumab
- Generic name
- Etaracizumab
- Host animal
- Mouse
- Name
- MC (maleimidocaproyl)
- Description
- Noncleavable linkers, is considered noncleavable-meaning linker cleavage, and payload release does not depend on the differential properties between the plasma and some cytoplasmic compartments. Instead, the release of the cytotoxic drug is postulated to occur after internalization of the ADC via antigen-mediated endocytosis and delivery to lysosomal compartment, where the antibody is degraded to the level of amino acids through intracellular proteolytic degradation.
- Name
- MMAF
- Description
- Derived from Auristatin,are water-soluble dolastatin analogs of dolastatin 10. Dolastatin 10 belongs to dolastatin family and it can powerfully bind to tubulin, thus inhibiting polymerization mediated through the binding to the vinca alkaloid binding domain, and causes cell to accumulate in metaphase arrest.
For Research Use Only. NOT FOR CLINICAL USE.
Related Products
- Anti-TPBG (E380C)-VC-MMAD ADC (CAT#: ADC-W-164)
- Anti-C. diff Toxin A (Actoxumab)-SMCC-DM1 ADC (CAT#: ADC-W-2048)
- Anti-IL6 (Siltuximab)-MC-Vc-PAB-SN38 ADC (CAT#: ADC-W-1428)
- Anti-HGF (Flanvotumab)-MC-Vc-PAB-MMAE ADC (CAT#: ADC-W-1193)
- Anti-LOXL2 (Simtuzumab)-MC-Vc-PAB-MMAE ADC (CAT#: ADC-W-1529)
- Anti-DLL4 (Demcizumab)-MC-Vc-PAB-MMAE ADC (CAT#: ADC-W-1019)
- Anti-CD33 (clone h2H12)-Mc-MMAF ADC (CAT#: ADC-W-115)
- Anti-CD79B (Polatuzumab )-SPDB-DM4 ADC (CAT#: ADC-W-2555)
- Anti-ITGA2 (Vatelizumab)-SMCC-DM1 ADC (CAT#: ADC-W-1454)
- Anti-TNF (Golimumab)-SMCC-DM1 ADC (CAT#: ADC-W-1820)
Published Data
+ Submit Publications
Scientific Resources
Customer Reviews and FAQs
There are currently no Customer reviews or questions for ADC-W-2128. Click the button above to contact us or submit your feedback about this product.
Quick Links
Other Products
Same Target
Same Linker
Same Payload
CAT# | Product Name | Linker | Payload |
ADC-W-2127 | Anti-ITGAV+ITGB3 (Etaracizumab)-SPDB-DM4 ADC | SPDB (N-succinimidyl-4-(2-pyridyldithio)butyrate) | DM4 (N2'-Deacetyl-N2'-(4-mercapto-4-methyl-1-oxopentyl)maytansine) |
ADC-W-2126 | Anti-ITGAV+ITGB3 (Etaracizumab)-SMCC-DM1 ADC | SMCC (N-succinimidyl 4-(Nmaleimidomethyl)cyclohexane-1-carboxylate) | DM1 (N2'-Deacetyl-N2'-(3-mercapto-1-oxopropyl)maytansine) |
ADC-W-2130 | Anti-ITGAV+ITGB3 (Etaracizumab)-MC-Vc-PAB-SN38 ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | SN-38 (7-ethyl-10-hydroxycamptothecin) |
ADC-W-2131 | Anti-ITGAV+ITGB3 (Etaracizumab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC | MC-Vc-PAB-DMEA-(PEG2) | duocarmycin SA |
ADC-W-2129 | Anti-ITGAV+ITGB3 (Etaracizumab)-MC-Vc-PAB-MMAE ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | MMAE |
CAT# | Product Name | Linker | Payload |
ADC-W-2622 | Anti-NCAM1 (Lorvotuzumab )-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
ADC-W-452 | Anti-CD70 (clone 1F6)-Mc-MMAF ADC | Mc (maleimidocaproyl) | MMAF (Monomethyl auristatin F) |
ADC-W-322 | Anti-CD19 (clone hBU12)-Mc-MMAF ADC | Mc (maleimidocaproyl) | MMAF (Monomethyl auristatin F) |
ADC-W-491 | Anti-TNFRSF17-Mc-MMAF ADC | Mc (maleimidocaproyl) | MMAF (Monomethyl auristatin F) |
ADC-W-515 | Anti-EGFR (ABT-806)-Mc-MMAF ADC | Mc (maleimidocaproyl) | MMAF (Monomethyl auristatin F) |
CAT# | Product Name | Linker | Payload |
ADC-W-2591 | Anti-EGFR (Cetuximab)-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
ADC-W-2573 | Anti-SLC34A2 (Lifastuzumab )-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
ADC-W-2550 | Anti-CD74-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
ADC-AA-064 | Anti-HIgG(Fab)-C-MMAF ADC | Cleavable linkers | MMAF |
ADC-W-2579 | Anti-CEACAM5-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
Online Inquiry
Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.